Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15%

  • Posted by: Biocon Biologics

Deepali Naair Appointed as the Global Head – Brand & Corporate Communications at Biocon Biologics

  • Posted by: Biocon Biologics

Biocon Biologics Launches Nepexto®, a Biosimilar to Enbrel® (Etanercept), in Australia

  • Posted by: Biocon Biologics

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States

  • Posted by: Biocon Biologics

Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars

  • Posted by: Biocon Biologics

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

  • Posted by: Biocon Biologics

Biocon Biologics Expands Insulin Access in Malaysia

  • Posted by: Biocon Biologics

Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025

  • Posted by: Biocon Biologics

Biocon Biologics Collaborates with National Cancer Society Malaysia

  • Posted by: Biocon Biologics

Biocon Foundation in Partnership with NCBS and BeST Cluster Launches BioWISE Program – to Empower Women in STEM

  • Posted by: Biocon Biologics
Share
buy twitter followers - deneme bonusu veren siteler - deneme bonusu veren siteler - deneme bonusu veren siteler - deneme bonusu veren siteler - takipcimx 1000 - buy facebook followers -

çekişmeli boşanma avukatı

- volgers kopen - marsbahis giriş